365 related articles for article (PubMed ID: 25600562)
1. Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER-Medicare analysis.
Malhotra J; Mhango G; Gomez JE; Smith C; Galsky MD; Strauss GM; Wisnivesky JP
Ann Oncol; 2015 Apr; 26(4):768-773. PubMed ID: 25600562
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant treatment for elderly patients with early-stage lung cancer treated with limited resection.
Veluswamy RR; Mhango G; Bonomi M; Neugut AI; Hershman DL; Aldridge MD; Wisnivesky JP
Ann Am Thorac Soc; 2013 Dec; 10(6):622-8. PubMed ID: 24024700
[TBL] [Abstract][Full Text] [Related]
3. Outcomes after adjuvant platinum-based chemotherapy in elderly NSCLC patients with T4 disease.
Sigel K; Mhango G; Cohen J; Halm EA; Mandeli J; Strauss G; Wisnivesky J
Ann Surg Oncol; 2013 Mar; 20(3):1013-9. PubMed ID: 23115004
[TBL] [Abstract][Full Text] [Related]
4. Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
Wang J; Wu N; Lv C; Yan S; Yang Y
J Cancer Res Clin Oncol; 2019 Feb; 145(2):463-469. PubMed ID: 30474757
[TBL] [Abstract][Full Text] [Related]
5. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
[TBL] [Abstract][Full Text] [Related]
8. Gender, Age, and Comorbidity Status Predict Improved Survival with Adjuvant Chemotherapy Following Lobectomy for Non-small Cell Lung Cancers Larger than 4 cm.
Sandler BJ; Wang Z; Hancock JG; Boffa DJ; Detterbeck FC; Kim AW
Ann Surg Oncol; 2016 Feb; 23(2):638-45. PubMed ID: 26474557
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
[TBL] [Abstract][Full Text] [Related]
10. Impact of adjuvant chemotherapy in stage IB non-small-cell lung cancer: an analysis of 112 consecutively treated patients.
Dediu M; Ion O; Ion R; Alexandru A; Median D; Gal C; Horvat T; Motas C; Motas N
J BUON; 2012; 17(2):317-22. PubMed ID: 22740212
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003.
Morgensztern D; Waqar S; Subramanian J; Gao F; Trinkaus K; Govindan R
J Thorac Oncol; 2012 Oct; 7(10):1479-84. PubMed ID: 22982648
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
13. Lung cancer in women, a different disease: survival differences by sex in Turkey.
Ulas A; Tokluoglu S; Kos M; Silay K; Akinci S; Oksuzoglu B; Alkis N
Asian Pac J Cancer Prev; 2015; 16(2):815-22. PubMed ID: 25684531
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy for non-small cell lung cancer: practice patterns and outcomes in the general population of Ontario, Canada.
Booth CM; Shepherd FA; Peng Y; Darling G; Li G; Kong W; Mackillop WJ
J Thorac Oncol; 2012 Mar; 7(3):559-66. PubMed ID: 22307012
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung.
Chaft JE; Sima CS; Ginsberg MS; Huang J; Kris MG; Travis WD; Azzoli CG
J Thorac Oncol; 2012 Sep; 7(9):1400-5. PubMed ID: 22895138
[TBL] [Abstract][Full Text] [Related]
17. Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L.
Kogure Y; Ando M; Saka H; Chiba Y; Yamamoto N; Asami K; Hirashima T; Seto T; Nagase S; Otsuka K; Yanagihara K; Takeda K; Okamoto I; Aoki T; Takayama K; Yamasaki M; Kudoh S; Katakami N; Miyazaki M; Nakagawa K
J Thorac Oncol; 2013 Jun; 8(6):753-8. PubMed ID: 23575412
[TBL] [Abstract][Full Text] [Related]
18. Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials.
Hamada C; Tsuboi M; Ohta M; Fujimura S; Kodama K; Imaizumi M; Wada H
J Thorac Oncol; 2009 Dec; 4(12):1511-6. PubMed ID: 19875974
[TBL] [Abstract][Full Text] [Related]
19. Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction.
Chhajed PN; Baty F; Pless M; Somandin S; Tamm M; Brutsche MH
Chest; 2006 Dec; 130(6):1803-7. PubMed ID: 17167000
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer in the U.S. National Cancer Data Base.
Osarogiagbon RU; Lin CC; Smeltzer MP; Jemal A
J Thorac Oncol; 2016 Jan; 11(1):e5-16. PubMed ID: 26762752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
